

Freedom of Information Request: Our Reference CTMUHB_416_21

You asked:

1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

Please see provided below a table populated with the data that is captured on our Medicines Management system. The data period relates to 1st May 2021 to 31st August 2021 as requested.

Medicine	Number of Patients
Aflibercept	865
Bevacizumab	17
Brolucizumab	0
Dexamethasone	18
Fluocinolone acetonide	0
Ranibizumab	32

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

This level of information is not captured on our Medicines Management system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl through all the Dermatology patients treated within this timeframe and would significantly exceed the 18 hours' time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

3. Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**

- **Dexamethasone**
- **Ranibizumab**

Please see provided below a table populated with the data that is captured on our Medicines Management system. The data period relates to 1st May 2021 to 31st August 2021 as requested.

Medicine	Number of Injections
Aflibercept	1990
Bevacizumab	28
Brolucizumab	0
Dexamethasone	26
Ranibizumab	66

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Ranibizumab**

Please see response to question 2.